Back to Results

Petros Pharmaceuticals Inc (PTPI)

Petros Pharmaceuticals, Inc. is a healthcare technology company focused on developing and licensing proprietary software products for the pharmaceutical industry. Its offerings include a SaaS platform and a software-as-a-medical-device web application designed to support pharmaceutical companies. The company is based in New York, New York. Petros Pharmaceuticals common stock trades on OTC Markets under the symbol PTPI.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
OTC-PTPI
$0.0080
100.0% Upside
Bargain
Not available
Not available
Fair
0.0%
November 13, 2026
0.4x
169.49 K
-3.234 M
0.0%
68.3%
-105.7
21.4%
Valuation • Fair Value

Petros Pharmaceuticals Inc (OTC-PTPI) Fair Value by Valuation Model

Review the available estimates for Petros Pharmaceuticals Inc (OTC-PTPI), including Comps Fair Value.

Primary Valuation Read

Fair Value

$0.0080

Estimated upside of 100.0% versus the current market price.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

Comps Fair Value

$0.0080

Comparable-company valuation reference.

Analyst Price Target

Not available

Data is currently unavailable.

How to read these valuation models

Use the 3 available valuation references for Petros Pharmaceuticals Inc (OTC-PTPI) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Petros Pharmaceuticals Inc (OTC-PTPI)

Review the profitability and growth indicators currently supported by the latest data.

Revenue Forecast

5.453 M

Forward revenue estimate.

EBITDA

0 K

Current operating profitability reference.

How to read profitability and growth

This section helps investors review Petros Pharmaceuticals Inc (OTC-PTPI) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Petros Pharmaceuticals Inc (OTC-PTPI)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

2

Weak quality score that deserves closer review.

Altman Z-Score

-105.7

Lower score that deserves closer risk review.

FCF / Net Income

21.4%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Petros Pharmaceuticals Inc (OTC-PTPI). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Petros Pharmaceuticals Inc (OTC-PTPI)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 13, 2026

Days to Earnings

56

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for Petros Pharmaceuticals Inc (OTC-PTPI), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Technical Outlook

Technical Signals by Time Frame

Review the technical signals currently available for this stock across supported time frames.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Petros Pharmaceuticals Inc (OTC-PTPI) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Petros Pharmaceuticals Inc (OTC-PTPI) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Petros Pharmaceuticals Inc (OTC-PTPI) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Petros Pharmaceuticals Inc (OTC-PTPI) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Petros Pharmaceuticals Inc (OTC-PTPI) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

FAQ • Fast Investor Answers

Petros Pharmaceuticals Inc (OTC-PTPI) Stock FAQ

Data-supported answers about Petros Pharmaceuticals Inc (OTC-PTPI), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$0.0080
Estimated upside 100.0%
Valuation Rating
Undervalued
Estimated upside of 100.0%
Financial Health
Fair
Current financial-health read

The current fair value estimate for Petros Pharmaceuticals Inc (OTC-PTPI) is $0.0080. This implies an estimated upside of 100.0% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 100.0% versus the current market price.

The current financial health read for Petros Pharmaceuticals Inc (OTC-PTPI) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Petros Pharmaceuticals Inc (OTC-PTPI) is November 13, 2026.

The latest available data indicates no current dividend yield for Petros Pharmaceuticals Inc (OTC-PTPI).

The current market capitalization listed for Petros Pharmaceuticals Inc is 169.49 K.

The current enterprise value listed for Petros Pharmaceuticals Inc is -3.234 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Petros Pharmaceuticals Inc is OTC-PTPI, and the stock is listed on OTC Markets.

Petros Pharmaceuticals Inc (OTC-PTPI) is listed on OTC Markets.

The current debt-to-total-capital ratio listed for Petros Pharmaceuticals Inc is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Petros Pharmaceuticals Inc is 68.3%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on OTC Markets

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,027.7 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 650.6 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 362.4 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 266.2 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 191.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 157.7 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 128.8 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 101.9 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 100.8 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.801 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 45.423 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.198 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.653 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 29.504 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.446 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.628 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Fair Market Cap 11.943 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.202 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.884 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.161 B